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Abstract
Background: Lymph node status is an important prognostic factor and a criterion for adjuvant therapy in uterine
cancers. While detection of micrometastases by ultrastaging techniques is correlated to prognosis in several other
cancers, this remains a matter of debate for uterine cancers. The objective of this review on sentinel nodes (SN) in
uterine cancers was to determine the contribution of ultrastaging to detect micrometastases.
Methods: Review of the English literature on SN procedure in cervical and endometrial cancers and histological
techniques including hematoxylin and eosin (H&E) staining, serial sectioning, immunohistochemistry (IHC) and
molecular techniques to detect micrometastases.
Results: In both cervical and endometrial cancers, H&E and IHC appeared insufficient to detect micrometastases. In
cervical cancer, using H&E, serial sectioning and IHC, the rate of macrometastases varied between 7.1% and 36.3%
with a mean value of 25.8%. The percentage of women with micrometastases ranged from 0% and 47.4% with a
mean value of 28.3%. In endometrial cancer, the rate of macrometastases varied from 0% to 22%. Using H&E, serial
sectioning and IHC, the rate of micrometastases varied from 0% to 15% with a mean value of 5.8%. In both
cervical and endometrial cancers, data on the contribution of molecular techniques to detect micrometastases are
insufficient to clarify their role in SN ultrastaging.
Conclusion: In uterine cancers, H&E, serial sectioning and IHC appears the best histological combined technique to
detect micrometastases. Although accumulating data have proved the relation between the risk of recurrence and
the presence of micrometastases, their clinical implications on indications for adjuvant therapy has to be clarified.
Introduction
Studies conducted in the 90’s reported that sensitive
immunochemical and/or molecular techniques used to
analyze lymph nodes likely to contain metastases could
assess the clinical stage to a previously unachievable
degree of accuracy (ultrastaging) [1,2]. In a 1997 study
of 595 patients with melanoma, Joseph et al evaluated
the contribution of serial sectioning, immunohistochem-
istry (IHC) and a molecular technique with reverse tran-
scriptase polymerase chain reaction (RT-PCR) to routine
hematoxylin and eosin (H&E) histology to detect lymph
node metastases. The study showed that routine H&E
histology identified 73.8% of all metastases [3]. The
remainder was detected by serial sectioning (7.8%) and
IHC staining (18.4%) [3]. Moreover, RT-PCR upstaged
47% of the negative sentinel lymph nodes (SLN) [3]. In
breast cancer, Cote et al reported that serial sectioning
and IHC were able to detect respectively 7% and 20% of
metastases in negative lymph nodes on H&E histology
[1]. In 2001, a multicenter study of stage I-III colorectal
cancer by Saha et al. reported that serial sectioning and
IHC detected lymph node micrometastases in 14% of
patients [4].
The concept of ultrastaging implies that lymph nodes
be systematically analysed using serial sectioning and
IHC. However, histological and/or molecular techniques
used to assess ultrastaging on all nodes are time con-
suming and expensive thus limiting its routine use.
Hence, the concept of ultrastaging is inseparable from
that of SLN biopsy [5]. In melanoma, breast cancer, vul-
var and colon cancers, the relevance of SLN biopsy has
been validated and is considered an alternative to com-
prehensive lymphadenectomy to assess lymph node sta-
tus. Although accumulating data on SLN in uterine
cancers are available, its validation remains a matter of
debate especially for endometrial cancers due to the
absence of consensus on the SLN technique. Moreover,
few data are available on ultrastaging in uterine cancers.
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uate the contribution of ultrastaging in uterine cancers
and its potential therapeutic implications.
Concept of ultrastaging in uterine cancers
Despite favourable prognostic features, pelvic recurrence
occurs in up to 15% of patients with early stage cervical
cancer and histologically negative pelvic lymph nodes by
routine examination using H&E staining [6,7]. Holmg-
ren et al. suggested that some of these recurrences
could be due to metastases not detected by routine
H&E histology of lymph nodes, so-called “dormant” or
“occult” metastases [8]. Hafner et al. reported that using
routine H&E histology, the chances of identifying a
tumour cell cluster of less than 3 cell diameters was
only 1% [9].
In 2003, Dargent and Enria evoked the concept of
micrometastases without clear histological definition in
cervical cancer. They reported that the use of serial sec-
tioning and IHC gave a possible tenfold increase in
detecting micrometastases [10]. Moreover, as microme-
tastases were found when the technique was retrospec-
tively applied to lymph nodes from women with
recurrence, the relevance of both serial sectioning and
IHC and its prognostic value emerged along with the
concept of ultramicroscopic staging. In contrast to mela-
noma and breast cancer, there is an absence of universal
agreement on the definition of lymph node metastases
in cervical cancer. Following the Philadelphia Consensus
Conference on sentinel nodes in breast cancer [11], defi-
nitions have been proposed: macrometastases as a single
focus of metastatic disease per node measuring more
than 2 mm, micrometastases as a focus of metastatic
disease ranging from 0.2 mm to no more than 2 mm
and, in accordance with Marchiolé et al, submicrometas-
tases as metastases measuring no more than 0.2 mm
(including the presence of a single non-cohesive tumor
cell) [12]. SLN and pelvic lymph nodes are considered
positive when they contain macrometastases, microme-
tastases or submicrometastases.
In 2004, histological validation of the concept of SLN
biopsy in cervical cancer was demonstrated by Barranger
et al [13]. Despite the small sample size, the contribu-
tion of serial sectioning and IHC to ultrastaging was
evoked. In 2007, the same team validated the histologi-
cal concept of SLN biopsy for endometrial cancer [14].
But, in contrast to cervical cancer, no standardization of
the SLN procedure in endometrial cancer existed.
Concerns on ultrastaging protocols
Ultrastaging protocols vary from one study to another
and there is no validation of a standardized routine pro-
tocol to date. This has been emphasized recently in an
editorial by Gien & Covens on quality control in senti-
nel node biopsy [15]. Results of ultrastaging depend on
several factors including the technique of intraoperative
histology, the technique of serial sectioning and the
antibodies used for IHC.
Imprint cytology has been proved to have a low accu-
racy to detect micrometastases in both cervical and
endometrial cancer but has the advantage of preserving
tissue for definitive histology [16]. However, no trial has
compared the accuracy of imprint cytology to that of
frozen section. So far, insufficient data are available to
evaluate the contribution of molecular techniques to
assess metastases intraoperatively. Yet, detecting metas-
tases during surgery is required to extend lymphade-
nectomy to the paraaortic area.
Serial sectioning is often mentioned in the material
and methods section of published reports but the exact
histological technique is rarely described. Under the
term of serial sectioning various conditions exist. The
number of levels ranged from one additional level to up
to five additional levels and the interval between levels
ranged from 40 to 250 μm [17]. However, the technique
of serial sectioning is crucial for adequate staging and
reducing the false negative rate [1,14]. Even though
most of the publications on SLN series report using
cytokeratin (CK) antibodies for IHC staining, serial sec-
tioning with H&E staining is not systematically used
[17]. In endometrial cancer some studies have confirmed
that the number of histological sections plays a crucial
role in detecting metastases. Reich et al using serial-step
section at 600 to 800 μm intervals, reported that metas-
tases measuring less than 2 mm were detected in up to
50% of patients [2].
Most studies purport that the optimal method for
ultrastaging includes an IHC. The signal amplification
produced by immunodetection facilitates disease detec-
tion compared with H&E. In uterine cancers, the types
of antibodies used for IHC staining varied according to
the series. Although the majority of authors used anti-
CK AE1 and AE3, some authors recommended anti-
pancytokeratine KL1. In contrast, CAM antibodies are
rarely used even though this antibody differentiates true
metastases from mesothelial staining.
In cervical cancer, Lentz et al [18] using the IHC
without serial sectioning reported that IHC detected
micrometastases in 19 out of a series of 132 women
with 3,106 negative lymph nodes on routine histology
(15%, 95% interval confidence (IC): 9%-22%). Silva et al
emphasized the contribution of IHC in detecting micro-
metastases in a series of 52 patients with stage I-II cervi-
cal cancer [19]. In their study, IHC detected
micrometastases in five out of 98 negative SLN. Barran-
ger et al in the report on histological validation of SLN
in cervical cancer noted that micrometastases were
found in two of the five patients with metastases with
the use of IHC [13]. As underlined by Euscher et al, the
ultrastaging protocol for negative sentinel node on
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μm thick), each obtained at 5 levels (40 μmi n t e r v a l ) .
Then, a first section of each level was stained with H&E.
The two unstained sections at each level were available
for additional analysis when atypical cells were detected
on H&E. When the five additional H&E stained levels
were negative, then an unstained section from the first
level was stained with a keratin cocktail to confirm the
negative histologic impression. This keratin cocktail was
composed of 4 antibodies: AE1/AE3, CAM 5.2, Cytoker-
atin MNF116, Keratin 8 and 18 allowing both to detect
metastasis as well as to differentiate true metastasis
from benign inclusion [17]. In breast cancer, Cote et al.,
evaluated the contribution of serial sectioning (2 sec-
tions from each of six levels) and immunohistochemistry
(2 anticytokeratins AE-1 and a CAM 5.2) to the routine
histology (ref) and detected 20% of additional microme-
tastasis [1].
In a case control study in women with cervical cancer,
Marchiole et al showed that IHC detected micrometas-
tases in 23% of patients [12]. These authors also under-
lined the risk of false positive cases of micrometastases
related to benign glandular inclusions. Marchiolé et al.
noted that even RT-PCR had a better sensitivity than
IHC, this is counter balanced by a lack in specificity.
Indeed, it is not possible to differentiate macrometasta-
sis from benign glandular inclusion using only RT-PCR.
Moreover, even a correlation has been established
between the number of copy cells and the size of metas-
tases, RT-PCR is enable to differentiate true macrome-
tastases from multiple micrometastasis or
submicrometastasis.
Similar results have been observed by Nickles-Fader et
al [20] reporting that one of the three suspected micro-
metastases corresponded to mesothelial staining.
In endometrial cancer, similar results showing that
IHC based on CK staining may improve the sensitivity
of detecting metastasis compared with H&E staining
have been reported [21,22]. In a pilot study using H&E
histology and IHC without serial sectioning [21], 12.5%
of patients with negative pelvic lymph nodes on H&E
exhibited metastases by IHC. Niikura et al [23] using
serial sectioning and IHC noted that micrometastases or
isolated tumour cells were detected in four out of 24
negative SLN (5% of patients) and in four out of 1,350
non SLN. These results have been confirmed by other
teams, Fersis et al. [24] and Pelosi et al. [25]. Finally,
Barranger et al in their report on histological validation
of SLN in endometrial cancer, showed that IHC and
serial sectioning detected micrometastases in three out
of five patients with lymph node metastases [13].
Advances in the understanding of cellular biology
combined with developments in molecular technology
have provided new methods for the detection of
metastatic cancer cells, which are likely to be more sen-
sitive than conventional histology. This molecular biol-
ogy-based ultrastaging of cancer is already part of the
standard management of patients with hematologic
malignancies. However, the search for minimal residual
disease by means of molecular biology techniques in
solid tumours remains controversial. In melanoma,
although ten studies have been performed and thou-
sands of patients enrolled, there is no consensus on
whether molecular biology-based detection of microme-
tastases has a prognostic power reliable enough to be
implemented in routine clinical practice [26]. In a 2001
study on cervical cancer, Van Trappen et al evaluated
the use of RT-PCR to detect CK-19 in pelvic lymph
nodes [27]. CK-19 expression was correlated to lymph
node status. However, Coutant et al reported a low cor-
relation between CK-19 expression by RT-PCR and SLN
status [16]. Recently, Yuan et al [28] using the same
technique as Van Trappen et al reported a wide overlap-
ping in CK-19 expression between positive and both
negative SLN and non-SLN. Yuan et al suggested that
detection by RT-PCR of squamous cell carcinoma anti-
gen (SCCA) was more accurately associated with lymph
node status than CK-19 expression. The expression
levels of squamous cell carcinoma antigen (SCCA), CK
19 and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA in 178 samples were assessed by PCR
[28]. The authors used a fully quantitative real-time RT-
PCR and avoid amplification and detection of CK 19
genes [28]. Their results showed that CK19 is not a sui-
table marker for molecular diagnosis of SLN metastasis
in cervical cancer because of its low specificity in nor-
mal lymph node and showed that SCCA is a better mar-
ker than CK19 [28].
Hafner et al [9] suggested that E6 expression was
linked to lymph node status but, as in previous studies
[27,28], there was a high overlapping of values between
positive and negative lymph nodes. Coutant et al
reported that HPV DNA screening in SLN by means of
PCR might help to identify patients at risk of lymph
node metastases and recurrence although HPV DNA
was noted in only 46.7% of positive SLN and in 13.6%
of negative SLN [29]. While molecular techniques (such
as RT-PCR) may be more sensitive than IHC, they carry
a high false positive rate [30]. Indeed, Van Trappen et al
underlined that specific tumour DNA found in histolo-
gically normal lymph nodes may originate from dead
cell material or macrophages and that viral DNA can be
found in various cell types thus limiting its usefulness as
a molecular marker for micrometastases [27]. Marchiolé
et al noted that even RT-PCR had a better sensitivity
than IHC though this is counterbalanced by a lack of
specificity [12]. Moreover, it is not possible to differenti-
ate macrometastasis from benign glandular inclusion
Bézu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:5
http://www.jeccr.com/content/29/1/5
Page 3 of 8using only RT-PCR. In addition, even if a correlation
has been established between the number of copy cells
and the size of metastases, RT-PCR lacks accuracy in
differentiating true macrometastases with proved prog-
nostic value from multiple micrometastases or submi-
crometastases with questionable clinical relevance.
In endometrial cancer few data are available on the
contribution of molecular techniques to detect lymph
node metastases. Fishman et al were the first to report a
high CK-20 expression by RT-PCR in primary tumours
and in pelvic lymph nodes. Among the 18 patients with
negative pelvic lymph nodes by routine H&E histology,
six (33%) were CK-20 positive suggesting a potential
contribution of molecular biology in assessing lymph
node status. So far, no data are available on CK-20
expression by RT-PCR in SLN in patients with endome-
trial cancer [31].
Incidence of micrometastases and potential clinical
implications in patients with uterine cancers
The definition of micrometastases is rarely clearly men-
tioned in published reports representing a potential bias
in the interpretation of their prognostic relevance.
Moreover, as previously noted, the incidence of micro-
metastases can differ significantly according to the histo-
logical and biological technique used.
In cervical cancer, whatever the histological technique
used for detecting lymph node involvement, the rate of
macrometastases varied from 7.1% to 42% (table 1, 2).
Four studies have performed a histological analysis of
lymph nodes using H&E and IHC [32-35]. In the series
o fK r a f te ta li n c l u d i n g5 4patients, overall rate of
macrometastases was 42% but there was no mention of
the rate of micrometastases [35]. In the three remaining
studies including 65 patients, the rate of macrometas-
tases varied from 10% to 18.2% but none of the studies
reported detecting micrometastases. Although the total
number of patients included in these series was low, it
is possible to suggest that H&E and IHC are insufficient
to detect micrometastases.
Thirteen studies have used the combination of H&E,
serial sectioning and IHC [10,19,28,36-44]. In four of
the thirteen studies no attempt to evaluate the presence
of micrometastases was noted. In the remaining nine
studies involving 356 patients the rate of
macrometastases varied between 7.1% and 36.3% with a
mean value of 25.8% (92/356). Among patients with
lymph node metastases, the percentage of women with
micrometastases ranged from 0% and 47.4% with a
mean value of 28.3%. Therefore, at least one quarter of
patients with lymph node metastases exhibited
micrometastases.
Few data are available on the contribution of molecu-
lar biology to detect micrometastases. In Wang et al’s
series, the combination of H&E, serial sectioning, IHC
and CK-19 expression by RT-PCR detected macrome-
tastases in 18 out of 46 patients (39%) with lymph node
metastases and micrometastases in 7 out of the 18
patients (38.9%) with macrosmetastases [45]. For Cou-
tant et al, HPV DNA analysis in conjuction with H&E,
serial sectioning and IHC detected macrometastases in
15 out of 59 patients including three with micrometas-
tases (20%) [29].
In endometrial cancer, whatever the histological tech-
nique used for detecting lymph node involvement, the
rate of macrometastases varied from 0% to 22% (table 3,
4).
Seven studies reported a histological analysis of lymph
nodes using H&E [46-52]. The rate of macrometastases
varied from 8% to 22% but none of the studies reported
the detection of micrometastases. As for cervical cancer,
the use of H&E alone was unable to detect micrometas-
tases confirming that this technique is insufficient to
stage endometrial cancer. The combination of H&E to
IHC was used in two studies [23,25]. The contribution
of IHC was particularly relevant as respectively 18% and
20% of patients were upstaged after detection of
micrometastases.
Six studies have used the combination of H&E, serial
sectioning and IHC to detect micrometastases
[14,53-57]. The rate of micrometastases varied from 0%
to 15%. Among the 238 patients with endometrial can-
cer, the overall rate of lymph node metastases was
19.7% including 5.8% with micrometastases. The most
striking data was observed in the series of Ballester et al
showing that 10 out of the 46 patients with endometrial
cancer exhibited lymph node metastases [56]. In their
study, three of the ten metastases corresponded to
macrometastases and seven to micro- or
Table 1 Ultrastaging of sentinel lymph node using H&E and IHC in patients with cervical cancer
Study Year Method of analysis Nb of patients FIGO stage Macrometastatic SLN (%) Micrometastatic SLN (%)
Lambaudie 2003 H&E +IHC 12 IA2-IB1 2 (18.2) 0
Niikura 2004 H&E +IHC 20 IB1-IIA 2 (10) 0
Martinez Palones 2004 H&E +IHC 23 IA2-IIA 3 (13) 0
Kraft 2006 H&E +IHC 54 IB1-III 21 (42) na
Total 109 28 (25.7)
SLN: sentinel lymph node; H&E: hematein eosin staining; IHC: immunohistochemy; SS: serial sectioning; HPV: human papilloma virus; na: not available
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tases and the three additional micrometastases were
detected by H&E while three micrometastases and one
submicrometastases were diagnosed by serial sectioning
and IHC.
The relation between micrometastases and the risk of
recurrence and prognosis have been demonstrated in an
increasing number of malignancies including breast can-
cer [1,58-60], vulvar cancer [61-63]; gastric cancer [64],
oesophageal cancer [65], colon cancer [66,67], prostate
cancer [68], and melanoma [26] suggesting that micro-
metastases should be an indication for adjuvant therapy.
In cervical cancer, although the prognostic relevance
of micrometastases has not yet been established, Jur-
etzka et al recommend adjuvant radiotherapy in the
event of detection of micrometastases [69]. Marchiolè et
al found that the relative risk of recurrence in presence
of true micrometastases (focus of metastatic disease ran-
ging from 0.2 mm to no more than 2 mm) was 2.30 (CI:
1.65-3.20, p < 0.01) and 2.22 (CI: 1.30-3.80, p = 0.09) in
the presence of submicrometastases (focus of metastatic
disease no more than 0.2 mm including the presence of
single non cohesive tumour cells) [13]. These authors
addressed the issue of adjuvant therapy in patients with
both lymphovascular space involvement and microme-
tastases [13]. However, despite a high incidence of
micrometastases in cervical cancer, Coutant et al failed
to demonstrate a relation between the presence of
micrometastases or submicrometastases and the recur-
rence rate, probably due to the small sample size and a
relative short follow-up [29].
In early stage endometrial cancer, Yabushita et al. [22]
analyzed the relation between disease recurrence and
presence of micrometastases by IHC in pelvic lymph
nodes. Although in their report, the term micrometas-
tases is used to refer to metastases in which tumor cells
were detected only by the IHC method and the term
occult metastasis refers to the presence of tumor cell
Table 2 Ultrastaging of sentinel lymph node using H&E, serial sectioning and IHC in patients with cervical cancer
Study Year Method of analysis Nb of patients FIGO stage Macrometastatic SLN (%) Micrometastatic SLN (%)
Lantzsch 2001 H&E +SS+IHC 14 IB1 1 (7.1) 0
Plante 2003 H&E +SS+IHC 70 IA-IIA 8 (13.1) 3 (37.5)
Dargent 2003 H&E +SS+IHC 70 IA1-IIB 19 (30.2) 9 (47.4)
Hubalewska 2003 H&E +SS+IHC 37 I-IIA 5 (13.5) na
Pijpers 2004 H&E +SS+IHC 34 early 12 (36.3) 4 (33)
Silva 2005 H&E +SS+IHC 56 IA2-IIA 17 (32.7) 3 (17.6)
Rob 2005 H&E +SS+IHC 183 IA2-IB2 35 (21.9) na
Angioli 2005 H&E +SS+IHC 37 IB1 6 (23) 0
Di Stefano 2005 H&E +SS+IHC 50 IA2-IIA 9 (20) 2 (22.2)
Frumovitz 2006 H&E +SS+IHC 50 IA2-IB1 9 (18.8) na
Wang 2006 H&E +SS+IHC+CK19PCR 46 early 18 (39) 7 (38.9)
Yuan 2007 H&E +SS+IHC 81 IB1-IIA 17(20.9) 4 (23.5)
Coutant 2007 H&E +SS+IHC+HPV DNA 59 IA-II 15 (25.4) 3 (20)
Lee 2007 H&E +HPV DNA 57 IB-IIA 11 (19.3) na
Hauspy 2007 H&E +SS+IHC 39 IA1-IIA 2 (5.2) na
Bats 2007 H&E +SS+IHC 25 IA2-IA1 3 (12) 1 (33)
Total 908 187 (20.6) 36 (19.2)
SLN: sentinel lymph node; H&E: hematein eosin staining; IHC: immunohistochemy; SS: serial sectioning; HPV: human papilloma virus; na: not available
Table 3 Ultrastaging of sentinel lymph node using H&E or H&E and IHC in patients with endometrial cancer
Study Year Method of analysis Nb of patients FIGO stage Macrometastatic SLN (%) Micrometastatic SLN (%)
Burke 1996 H&E 15 I-II 2 (13) na
Echt 1999 H&E 8 I-IV na na
Holub 2004 H&E 25 I 2 (8) na
Raspagliesi 2004 H&E 18 I-III 4 (22) na
Altgassen 2007 H&E 25 I-II 2 (8) na
Frumovitz 2007 H&E 18 I-II-III 0 na
Li 2007 H&E 20 I-II-III 2 (10) na
Pelosi 2003 H&E+IHC 16 I 3 18) 3 (18)
Niikura 2006 H&E+IHC 20 I-II-III 4 (20) 4 (20)
H&E: hematein eosin staining; IHC: immunohistochemy; SLN: sentinel lymph node; na: not available
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lymph node was associated with recurrence of disease in
univariate (p < 0.0001) and multivariate analysis (p =
0.009). However, as for cervical cancer, the debate on
whether the detection of micrometastases could be an
indicator of adjuvant therapy continues.
Conclusion
Although accumulating data emphasize the contribution
of serial sectioning and IHC to detect micrometastases,
the clinical implications of ultrastaging on adjuvant
therapy remains a matter of debate in uterine cancers.
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